Esperion Therapeutics | ESPR - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cipla INR 7.49B 4.2B 2026-03
CSL USD 2.61B 1.21B 2025-12
Cytokinetics USD -206.03M 23M 2026-03
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Geron USD -3.64M 27.5M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -799M 612M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12